Effect of Whenshen Prescription on Hepatic Encephalopathy in Patients with HBV-related Hepatic Cirrhosis and Content of HMGB1/TLR4
10.13422/j.cnki.syfjx.20190926
- VernacularTitle: 温肾方对乙肝肝硬化合并肝性脑病患者疗效及HMGB1，TLR4含量的影响
- Author:
Jian-xing LUO
1
;
Xiao-yu HU
1
Author Information
1. Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China
- Publication Type:Research Article
- Keywords:
Whenshen prescription;
hepatic encephalopathy;
HBV-related hepatic cirrhosis;
high mobility group protein B1 (HMGB1);
Toll-like receptor 4(TLR4);
NH3;
Haoqin Qingdantang;
Youguiwan
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2019;25(15):131-135
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of Whenshen prescription on hepatic encephalopathy in patients with HBV-related hepatic cirrhosis and kidney Yang deficiency syndrome and the content of high-mobility group protein B1 (HMGB1) and Toll-like receptor 4 (TLR4). Method:The 66 patients treated in the Hospital of Chengdu University of Traditional Chinese Medicine from August 2013 to January 2015 were included. A prospective, parallel controlled design was used. The 66 cases were randomly divided into treatment group and control group according to 1:1 ratio, with 33 cases in each group.The control group was treated with comprehensive therapy, colon dialysis and placebo enema, while treatment group was treated with comprehensive therapy, colon dialysis and Whenshen prescription enema for 10 days. Finally, liver function, number connect test (NCT), digit-symbol test (SDT), awake time, the total effective rate and content of HMGB1 and TLR4 were analyzed. Result:There was no significant difference between two groups at baseline. The total effective rate in treatment group was 93.9%, which was higher than 72.7% in control group (P<0.05). Plasma ammonia, liver function, awake time, NCT and SDT in treatment group were better than those in control group (P<0.05). The contents of HMGB1 and TLR4 in treatment group were lower than those in the control group. Conclusion:Whenshen prescription can significantly improve the clinical efficacy by inhibiting the contents of HMGB1 and TLR4.
